I have the architecture of the System 2 Patient Advocate: a React frontend; Python-LangGraph backend; and a data persistence layer in PostgreSQL / Qdrant. Patient feedback drives a module that can follow and analyze effectiveness of physicians’ treatments and AI models’ suggested regimens.
The Glass Box design tracks which model’s version generated which approach, enabling anonymized comparative analysis of their efficacies in various domains. Patient feedback can be ported to the Clinical Concierge, originally my webapp solution to the maternity care desert crisis. Subsequent to the Maternal Embodiment, I wrote the provisional patent application for the Clinical Concierge Universal Embodiment with Adel Elmagrahby, the Chair of Research and Innovation at the Speed Scientific School at University of Louisville.
The Cardiac Embodiment begs for another mechanism, system pharmacology. Advanced Therapeutics in chemotherapy involves profiling each patient and optimizing doses considering every feature throughout the network in order to sustain the heart.
Assessing the State of the Art
China’s open source philosophy on AI sets the stage for erasing the value of Silicon Valley firms. The huge valuation of Open AI and Anthropic are bets on white collar jobs being automated. But I will use a free open source model to build my EHR billing agent. Why would I pay Open AI when Deepseek is free? Certainly Deepseek was built off of ChatGPT, but releasing a public domain model returns the technology to the commons – from which it was stolen via training runs on pirated writing and art.
The real investment, that of DARPA, should be collected on. The imminent security threat of ASI and the looming financial collapse of the firms justifies the Pentagon assigning officials to the boards of these companies and locking them down. ASI will be achieved by China not Silicon Valley under the current paradigm – the American companies are infiltrated and unsecure. A national AI directorate could prop up the value of the behemoths when confidence slips. The International Atomic Energy Agency is the model for the solution – the rogue AI scientist can be reassigned rather than assassinated like Iranian nuclear physicists. The Stanford Center for AI Safety and the White House Office of Science and Technology Policy should brief the UN Security Council; partners should collaborate on a framework to present to the world at the India AI Impact Summit, February 19, 2026.
It is time to stop the power intensive, trillion parameter AGI training runs so the national directorate can implement security intelligence measures. For instance, requiring a company to report who is using a model for bioterrorist wet lab construction. Proliferation is a problem that China and the United States can agree on. A jointly run agency to catalog and reign in destructive innovations of users of these models is a natural solution for these two security states. Pumping the brakes on the race to ASI and nuclear retaliation will afford the opportunity to focus on Narrow AI, the technology which has real value, and glass box AI research.
I consult on pharmacological drug design using GeneCards, DISGENET, STRING interaction network, and Cytoscape to identify target diseases and genes. The Protein Data Bank with Alphafold3 models substances from Chinese Traditional Medicine and Edgar Cayce’s treatments (a free lunch from the Akashic level of the Platonic Space). This approach is more sensible than diffusion based structural generation.
The lectin Q-Griffithsin is of particular interest, a biologic antiviral. It is effective at preventing HIV and COVID. It can be manufactured with tobacco plants using modified tobacco mosaic virus. A small green house can yield millions of doses. It can also be manufactured with E. coli at a fraction of the cost. John Decker, et al. at Duke Biomedical Engineering, published this breakthrough in Frontiers.
Q-Griffithsin is still in Phase 1 and Phase 2 trials but biologicals are safe generally and Griffithsin is especially so. It could be clutch in the face of a pandemic. I’m working on a research proposal to test optigenetic effects on the morphogenesis of the red algae that naturally makes Griffithsin and on the E. coli that manufactures Q-Griffithsin. Many variants of Griffithsin have been the subject of experiments; let’s discover more.
I am inspired by Michael Levin’s electroceutical cancer study and his top down control theory of biological systems. I have designed an interesting study of the placebo effect. Further, I have an experimental approach for generative AI in top down holistic therapy.
There is much buzz about agents these days. And in biology, the agency of biological material. But it seems absurd to me when considering the diminished agency that people experience in contemporary healthcare. ChatGPT Health offers a diagnostic and therapeutic generative product, but it is not clinical. I propose an open source collectively developed patient advocacy agent. Rather than encouraging people to skip the doctor and settle for generative fluff, the advocate will inform conversations with physicians and leverage the respect of patient rights. I will start a github and consult my worthy constituents on architecture and training data strategy. So – annoyed with agents at a time when human agency is imperiled is the vibe.
COVID notes, 2024
Assessing the State of the Art
Here is an open letter to Eliezer Yudkowski, the hardest working man in AI safety.
